Morgan Stanley Annovis Bio, Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,300 shares of ANVS stock, worth $3,549. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,300
Previous 1,350
3.7%
Holding current value
$3,549
Previous $10,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ANVS
# of Institutions
49Shares Held
1.37MCall Options Held
364KPut Options Held
494K-
Vanguard Group Inc Valley Forge, PA466KShares$1.27 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il215KShares$587,5150.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$274,9350.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$271,8090.0% of portfolio
-
Merit Financial Group, LLC98.5KShares$268,9480.01% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $22.3M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...